RNS Number : 1362I Renalytix PLC 03 August 2023 Renalytix plc ("Renalytix" or the "Company") Formation of Clinical Advisory Board Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd World leading, multi-disciplinary experts advise on adoption of FDA
Commercial availability of kidneyintelX.dkd™ expanded to an estimated 4 million DKD Patients in the Middle East Distribution agreement opens kidneyintelX.dkd testing to address early-stage kidney disease in region with one of the highest incidence rates for type 2 diabetes globally LONDON and SALT
RNS Number : 7254G Renalytix PLC 21 July 2023 Renalytix plc ("Renalytix" or the "Company") Middle East Distribution Agreement with Vector Pharma Commercial availability of kidneyintelX.dkd™ expanded to an estimated 4 million DKD Patients in the Middle East Distribution agreement opens
RNS Number : 2648G Renalytix PLC 17 July 2023 The following amendment has been made to the ' Issue of Shares' announcement released on 17 July 2023 at 07:00 under RNS No 1495G The correct figure for the principal remaining under the convertible bond after the settlement of the repayment is
RNS Number : 1495G Renalytix PLC 17 July 2023 Renalytix plc ("Renalytix" or the "Company") Issue of Shares LONDON and SALT LAKE CITY - July 17, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) , announces the repayment of $1.06 million of the Company's convertible bond, further details
12 Months KidneyIntelX™ in vitro prognostic testing continued to demonstrate clinical actions that lead to improvement in both diabetes (A1C reductions) and kidney health (eGFR slope improvement) in patients with Type 2 Diabetes and Chronic Kidney Disease LONDON and SALT LAKE CITY, July 07, 2023
RNS Number : 2729F Renalytix PLC 07 July 2023 Renalytix plc ("Renalytix" or the "Company") Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions 12 Months KidneyIntelX™ in vitro prognostic testing continued to demonstrate clinical actions that
RNS Number : 2612F Renalytix PLC 06 July 2023 Renalytix plc ("Renalytix" or the "Company") Grant of Share Options LONDON and SALT LAKE CITY - July 6, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled
LONDON and SALT LAKE CITY, July 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with Type 2 diabetes and chronic kidney disease, announces the
RNS Number : 7155E Renalytix PLC 03 July 2023 Renalytix plc ("Renalytix" or the "Company") Directorate Change Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors LONDON and SALT LAKE CITY - July 3, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the
